Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

XERIS BIOPHARMA HOLDINGS, INC.

(XERS)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Form 8.3 - The Vanguard Group, Inc. : Xeris Pharmaceuticals, Inc

09/22/2021 | 09:13am EDT

The Vanguard Group, Inc. ( irsh) Form 8.3 - The Vanguard Group, Inc.: Xeris Pharmaceuticals, Inc 22-Sep-2021 / 14:12 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.

-----------------------------------------------------------------------------------------------------------------------

Ap19

FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH IN INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION

Name of person dealing (Note 1)                                                  The Vanguard Group, Inc. 
Company dealt in                                                                 Xeris Pharmaceuticals, Inc. 
Class of relevant security to which the dealings being disclosed relate (Note 2) USD0.001 Common Stock 
Date of dealing                                                                  20 September 2021 

2. INTERESTS AND SHORT POSITIONS

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

                                             Long            Short 
                                             Numbers   (%)   Numbers (%) 
(1) Relevant securities                      2,965,892 4.46% 
(2) Derivatives (other than options) 
(3) Options and agreements to purchase/sell 
Total                                        2,965,892 4.46% 

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:                  Long        Short 
                                             Numbers (%) Numbers (%) 
(1) Relevant securities 
(2) Derivatives (other than options) 
(3) Options and agreements to purchase/sell 
Total 

Ap20

1. Dealings (Note 4)

(a) Purchases and sales

Purchase/sale Number of relevant securities  Price per unit (Note 5) 
Purchase      10,288                         2.37 USD 

(b) Derivatives transactions (other than options transactions)

Product name,  Nature of transaction Number of relevant securities Price per unit 
e.g. CFD       (Note 6)              (Note 7)                      (Note 5) 
Not Applicable 

(c) Options transactions in respect of existing relevant securities

(i) Writing, selling, purchasing or varying

Product name, Writing, selling,    Number of securities to               Type, e.g.               Option money paid/ 
              purchasing, varying  which the option relates     Exercise American,         Expiry received per unit 
e.g. call     etc.                 (Note 7)                     price    European etc.     date   (Note 5) 
option 
Not 
Applicable 

(ii) Exercising

Product name,                         Exercise price per unit (Note 5) 
                 Number of securities 
e.g. call option 
Not Applicable 

(e) Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction         Price per unit 
                      Details 
(Note 8)                      (if applicable) (Note 5) 
Not Applicable 

Ap21

2. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating 
to the voting rights of any relevant securities under any option referred to on this form or relating to the voting 
rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is 
referenced. If none, this should be stated. 
 
 
 
 

Is a Supplemental Form 8 attached? (Note 9) NO

Date of disclosure                                               22 September 2021 
Contact name                                                     Shawn Acker 
Telephone number                                                 001-610-669-8989 
If a connected EFM, name of offeree/offeror with which connected 
If a connected EFM, state nature of connection (Note 10) 

-----------------------------------------------------------------------------------------------------------------------

Category Code: RET - Xeris Pharmaceuticals, Inc 
TIDM:          irsh 
LEI Code:      5493002789CX3L0CJP65 
Sequence No.:  122780 
EQS News ID:   1235321 
 
End of Announcement  EQS News Service 
=------------------------------------------------------------------------------------
 

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1235321&application_name=news

(END) Dow Jones Newswires

September 22, 2021 09:12 ET (13:12 GMT)

All news about XERIS BIOPHARMA HOLDINGS, INC.
10/08XERIS BIOPHARMA HOLDINGS, INC. : Other Events (form 8-K)
AQ
10/05XERIS PHARMACEUTICALS INC : Notice of Delisting or Failure to Satisfy a Continued Listing ..
AQ
10/05XERIS PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Creation of a Dire..
AQ
10/05Xeris Pharmaceuticals, Inc. Announces Board Changes
CI
10/05XERIS PHARMACEUTICALS : Completes Acquisition of Strongbridge Biopharma
BU
10/01XERIS PHARMACEUTICALS : Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BU
09/22FORM 8.3 - THE VANGUARD GROUP, INC. : Xeris Pharmaceuticals, Inc
DJ
09/20FORM 8.3 - THE VANGUARD GROUP, INC. : Xeris Pharmaceuticals, Inc
DJ
09/20INVESCO LTD : Form 8.3 - Xeris Pharmaceutical Inc.
AQ
09/17FORM 8.3 - THE VANGUARD GROUP, INC. : Xeris Pharmaceuticals, Inc.
DJ
More news
Analyst Recommendations on XERIS BIOPHARMA HOLDINGS, INC.
More recommendations
Financials (USD)
Sales 2021 39,4 M - -
Net income 2021 -93,6 M - -
Net Debt 2021 - - -
P/E ratio 2021 -
Yield 2021 -
Capitalization 251 M 251 M -
Capi. / Sales 2021 6,36x
Capi. / Sales 2022 2,72x
Nbr of Employees 253
Free-Float -
Chart XERIS BIOPHARMA HOLDINGS, INC.
Duration : Period :
Xeris Biopharma Holdings, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends XERIS BIOPHARMA HOLDINGS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Managers and Directors
Paul R. Edick Chairman & Chief Executive Officer
John Patrick Shannon President & Chief Operating Officer
Steven M. Pieper Chief Financial Officer
Ken Johnson Senior VP-Global Development & Medical Affairs
Steven Prestrelski Chief Scientific Officer